Preparation and biodistribution assessment of low specific activity 177Lu-DOTATOC for optimization studies

Document Type : Original Article


1 Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran

2 Radiation Application Group, Faculty of Nuclear Engineering, Shahid Beheshti University, Tehran, Iran


Introduction: Somatostatin receptors expressed on a wide range of human tumors, are potential targets for the peptide receptor radionuclide therapy (PRRT). In this study, 177Lu-[DOTA-DPhe1, Tyr3]octreotide (177Lu-DOTATOC) as an agent for PRRT was prepared and its biodistribution was studied in rats.

Methods:The best condition for the preparation of the 177Lu-DOTATOC radiolabeled complex was determined by various experiments. Radiochemical purity of the radiolabeled complex was checked using ITLC method. The stability of the complex in room temperature and in human serum was studied up to 48 h. The biodistribution of 177Lu-DOTATOC solution was investigated in male rats at each selected interval time (2, 4, 24, 48, 72 and 168 h) after injection and compared with the biodistribution of 177LuCl3 solution in the same-type rats.

Results:177Lu-DOTATOC was prepared successfully with radiochemical purity of higher than 99% in 30 min at the optimized conditions. The stability of the radiolabeled complex at room temperature and in human serum at 37 °C showed no decrease in the radiochemical purity even after for 48 h. The biological behavior of the complex showed a major difference uptake with 177LuCl3 solution especially in the liver and spleen and also in somatostatin receptor-positive tissues such as pancreas and adrenal.

Conclusion: The results showed that 177Lu-DOTATOC has the comparable pharmacokinetic with the other DOTATOC complexes, while has completely different pattern compared with 177Lu cation.


Main Subjects

  1. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998 Jul;25(7):668-74.
  2. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):27-35.
  3. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(3 Suppl):S1-4.
  4. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res. 2013;194:353-71.
  5. Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, Ng QK, Mäcke HR, Müller-Brand J, Rochlitz C, Briel M, Walter MA. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012 Apr 1;30(10):1100-6. 
  6. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch CE. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006 Dec;140(6):968-76.
  7. Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005 Aug;46(8):1310-6.
  8. Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, Krogh K, Kjær A, Knigge U. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93(3):189-96.
  9. Dumont RA, Seiler D, Marincek N, Brunner P, Radojewski P, Rochlitz C, Müller-Brand J, Maecke HR, Briel M, Walter MA. Survival after somatostatin based radiopeptide therapy with 90Y-DOTATOC vs. 90Y-DOTATOC plus 177Lu-DOTATOC in metastasized gastrinoma. Am J Nucl Med Mol Imaging. 2015;5(1):46-55.
  10. Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, Maecke HR, Müller-Brand J, Rochlitz C, Briel M, Schindler C, Walter MA. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):214-22.
  11. Yousefnia H, Jalilian AR, Bahrami-Samani A, Mazidi M, Ghannadi Maragheh M, Abbasi-Davani F. Development of (177)Lu-phytate Complex for Radiosynovectomy. Iran J Basic Med Sci. 2013 May;16(5):705-9.
  12. Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, Gatti M, Chinol M, Bartolomei M, Fiorenza M, Grana C. 90Y-DOTA-D-Phe1-Tyr3-Octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2002;66(6):393–398.
  13. Akinlolu O: Combination 111In And 177Lu –Dotatoc and vaccinia virus oncolytic therapy for SSTR2-positive tumours.  MSc. thesis. University of Toronto. 2009.
  14. International Atomic Energy Agency. Comparative Evaluation of Therapeutic Radiopharmaceuticals. VIENNA: IAEA; 2007.
  15. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16.
  16. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10.
  17. Eberlein U, Lassmann M. Dosimetry of [⁶⁸Ga]-labeled compounds. Appl Radiat Isot. 2013 Jun;76:70-4.
  18. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, Larson SM. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002 Feb;29(2):147-57.
  19. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Henning M, Macke HR, Behe M. Radiometal-labelled macrocyclic chelator-derivatized somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J. 1999;5:1974–1981.